Predictors ID'd for Switching to Active Tx in Prostate Cancer

This article originally appeared here.
Share this content:
Predictors ID'd for Switching to Active Tx in Prostate Cancer
Predictors ID'd for Switching to Active Tx in Prostate Cancer

TUESDAY, Aug. 2, 2016 (HealthDay News) -- For men with low-risk prostate cancer, factors such as ethnicity influence patient decision to pursue active treatment during active surveillance, according to a study published online in The Journal of Urology.

Scott P. Kelly, Ph.D., from the Georgetown University Medical Center in Washington, D.C., and colleagues conducted a retrospective study involving 2,228 men diagnosed with low-risk prostate cancer who did not receive treatment within the first year of diagnosis. Factors associated with time from diagnosis to active treatment were examined.

The researchers found that 27 percent of the men began active treatment at a median of 2.9 years during follow-up. Compared with non-Hispanic white men, non-Hispanic black men were marginally more likely to begin active treatment, independent of baseline and follow-up clinical measures (hazard ratio [HR], 1.3; 95 percent confidence interval [CI], 1.0 to 1.7). Among those who remained on observation, rebiopsy within 24 months of diagnosis occurred at a slightly lower rate for non-Hispanic black than non-Hispanic white men (HR, 0.70; 95 percent CI, 0.60 to 1.0). Independent of race, Gleason grade progression (HR, 3.3; 95 percent CI, 2.7 to 4.1) and prostate-specific antigen doubling time less than 48 months (HR, 2.9; 95 percent CI, 2.3 to 3.7) correlated with active treatment initiation.

"Sociodemographic factors such as ethnicity and education may independently influence the patient decision to pursue active treatment and serial biopsies during active surveillance," the authors write.

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA Approves Bavencio for Merkel Cell Carcinoma

FDA Approves Bavencio for Merkel Cell Carcinoma

Drug targets the PD-1/PD-L1 pathway; first sanctioned treatment in the United States

Heterogeneous Association for Alcohol, CVD Presentation

Heterogeneous Association for Alcohol, CVD Presentation

Non-drinking linked to increased risks of unstable angina, MI, heart failure, ischemic stroke, PAD, AAA

Mobile App Cuts In-Person Visits After Breast Reconstruction

Mobile App Cuts In-Person Visits After Breast Reconstruction

Number of visits down, increase in e-mails to doctors for ambulatory patients undergoing breast recon

is free, fast, and customized just for you!

Already a member?

Sign In Now »